# OnCo record bevacizumab-glioma (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/bevacizumab-glioma/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "bevacizumab-glioma" ;
  schema:name "Bevacizumab (glioblastoma use)"@en ;
  schema:description "A blood-vessel-blocking antibody that shrinks glioblastoma on scans and reduces swelling, but has never been shown to help patients live longer."@en ;
  schema:url <https://onco.cc/drugs/bevacizumab-glioma/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bevacizumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q413299> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Bevacizumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-VEGF)" ;
  schema:alternateName "Avastin" ;
  onco:approval "US 2009: Recurrent glioblastoma (accelerated; full approval 2017)" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/vegf/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:pathways <https://onco.cc/pathways/vegf-angiogenesis/> ;
  onco:terms <https://onco.cc/terms/recist/> .